Biden Travels to Virginia to Talk Health Care

February 10, 2022 by Alexa Hornbeck
<strong>Biden Travels to Virginia to Talk Health Care</strong>
President Joe Biden speaks with Rep. Abigail Spanberger, D-Va., as he arrives on Marine One at Culpeper Regional Airport, Thursday, Feb. 10, 2022, in Brandy Station, Va. (AP Photo/Alex Brandon)

CULPEPER COUNTY, Va. — President Joe Biden traveled to Culpeper County, Virginia, Thursday delivering remarks intended to revive provisions of his now moribund Build Back Better agenda related to lowering health care costs and, particularly, prescription drug prices.

Mindful of a Labor Department report Thursday that found consumer prices jumped 7.5% last month — the steepest jump in 40 years — Biden said, “Just a little bit more breathing room makes a gigantic difference.” 

During his remarks, Biden said he would take steps to cap co-pays for prescription drugs and impose a “steep tax” on drug companies that raise their prices faster than the rate of inflation once the price is set.

He also said the administration will work to enforce discounts on prescription drugs for rural clinics and community health centers, and bring even more clarity and fewer surprises for those who are hospitalized. 

Biden said this could all be done through the Build Back Better legislation, which passed the House last year but has stalled in the Senate. 

Undeterred, Biden said his message to the big pharmaceutical companies is clear.

“You are finally going to become accountable when you raise prices on the American people,” he said.

According to the White House, one in four Americans who need prescription drugs struggle to afford them, and over the past decade health care costs have gone up about 50%. 

Health and Human Services Secretary Xavier Becerra accompanied the president to Culpeper County, and his remarks focused mainly on how the American Rescue Plan — the COVID-19 stimulus package passed last March — benefitted American consumers.

According to Becerra, about four in five people who recently signed up for health insurance through HealthCare.gov were able to find a plan where they pay less than $10 per month in premiums.

“Now that’s a good deal,” said Becerra.

What’s not a good deal, Becerra said, is that on average insured Americans still pay about $1,500 per person a year on prescription medications.

For months, the Build Back Better plan has appeared to be in the hands of Sen. Joe Manchin, D-W.Va., who announced in December 2021 that he couldn’t support the costly package passed in the House.

In the weeks since, there has been talk on Capitol Hill of a “slimmed down” version of Build Back Better, or a rolling out of its provisions individually, but actual progress on that front has been slow.

And as recently as last week, Manchin told reporters the bill is “dead.”

Biden appeared alongside Rep. Abigail Spanberger, D-Va., who may be in danger of losing her seat representing a central Virginia district.

Spanberger told the Associated Press that she welcomes any effort to lower prescription drug prices and told reporters that the effort was about a broader attempt to reduce inflation.

“That’s part and parcel of what we’re here talking about, right?” she said. “So when you’re worried about the gas pump or you’re worried about the cost of chicken in the grocery store, and your child is diabetic — all those things become impactful.” 

Alexa can be reached at [email protected]

A+
a-
  • Build Back Better
  • inflation
  • Joe Biden
  • Labor Department
  • prescription drug prices
  • Virginia
  • Xavier Becerra
  • In The News

    Health

    Voting

    Prescription Drugs

    April 24, 2024
    by Dan McCue
    FDA Approves New Treatment for Urinary Tract Infections

    WASHINGTON — The Food and Drug Administration approved Pivya (pivmecillinam) tablets for the treatment of female adults with uncomplicated urinary... Read More

    WASHINGTON — The Food and Drug Administration approved Pivya (pivmecillinam) tablets for the treatment of female adults with uncomplicated urinary tract infections.  “Uncomplicated UTIs are a very common condition impacting women and one of the most frequent reasons for antibiotic use,” said Dr. Peter Kim, M.S.,... Read More

    April 23, 2024
    by Beth McCue
    Study Finds Next-Gen Antibiotics Underutilized

    WASHINGTON — A new study conducted by researchers at the National Institutes of Health found clinicians frequently continue to treat... Read More

    WASHINGTON — A new study conducted by researchers at the National Institutes of Health found clinicians frequently continue to treat antibiotic-resistant infections with older generic antibiotics considered to be less effective and less safe than newer ones. Researchers examined the factors influencing doctors’ preference for older... Read More

    April 17, 2024
    by Dan McCue
    Eli Lilly Obesity Drug Appears to Ease Sleep Apnea Symptoms in Trials

    WASHINGTON — A pair of yearlong clinical trials conducted by the drug maker Eli Lilly appear to show that its... Read More

    WASHINGTON — A pair of yearlong clinical trials conducted by the drug maker Eli Lilly appear to show that its obesity drug, Zepbound, can provide considerable relief to overweight people who have sleep apnea. Though the findings have yet to be published in a peer-reviewed medical... Read More

    Many Cancer Drugs Remain Unproven Five Years After Accelerated Approval, a Study Finds

    The U.S. Food and Drug Administration’s accelerated approval program is meant to give patients early access to promising drugs. But how often... Read More

    The U.S. Food and Drug Administration’s accelerated approval program is meant to give patients early access to promising drugs. But how often do these drugs actually improve or extend patients’ lives? In a new study, researchers found that most cancer drugs granted accelerated approval do not demonstrate such... Read More

    ALS Drug Will Be Pulled From US Market After Study Showed Patients Didn't Benefit

    WASHINGTON (AP) — The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday it... Read More

    WASHINGTON (AP) — The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday it will pull the medicine from the market, acknowledging it didn't help patients with the deadly neurological condition. Amylyx Pharmaceuticals announced it will voluntarily halt sales and... Read More

    April 3, 2024
    by Dan McCue
    FDA Approves New Antibiotic for Three Different Uses

    WASHINGTON — The Food and Drug Administration on Wednesday approved the drug Zevtera for the treatment of adults with certain... Read More

    WASHINGTON — The Food and Drug Administration on Wednesday approved the drug Zevtera for the treatment of adults with certain bloodstream infections, those with acute bacterial skin and skin structure infections, and adult and pediatric patients 3 months to less than 18 years old with community-acquired... Read More

    News From The Well
    scroll top